Posts by Maxx Chatsko
Article
Maxx’s Top Stock for May 2022
May 1, 2022
7investing Lead Advisor Maxx Chatsko's top stock to buy in May 2022 serves as the linchpin of for biology-driven enterprises.
By Maxx Chatsko
Video
Maxx’s Top Stock for March 2022
Mar 1, 2022
7investing Lead Advisor Maxx Chatsko's top stock to buy in March 2022 is on the cusp of ramping three high-growth brands large, underserved markets.
By Maxx Chatsko
Article
Interacting with Members and Refining My Frameworks
Feb 22, 2022
Speaking with members has helped me to fine-tune my research process with clearer communication in mind.
By Maxx Chatsko
Premium Advisor Update
Will Solid-State Batteries Live Up to the Hype?
Feb 8, 2022
By Maxx Chatsko
Video
Maxx’s Top Stock for February 2022
Feb 1, 2022
7investing Lead Advisor Maxx Chatsko's top stock to buy in February 2022 has what might be the best technology stack and most methodical approach in molecular testing. That makes it well positioned...
By Maxx Chatsko
Article
Wild Prediction for 2022: CRISPR Stocks Become Mortal Again
Jan 22, 2022
Emerging therapeutic modalities built on the enzymatic tool will be subject to the traditional risk-reward calculus facing drug developers.
By Maxx Chatsko
Premium Advisor Update
Should You Invest in Synthetic Biology Stocks?
Jan 14, 2022
By Maxx Chatsko
Podcast
5 Big Reveals from the 2022 JP Morgan Healthcare Conference
Jan 13, 2022
7investing Lead Advisors Simon Erickson and Maxx Chatsko discuss a handful of big reveals from the first few days of the 2022 JP Morgan Healthcare Conference.
By Maxx Chatsko
Video
Maxx’s Top Stock for January 2022
Jan 1, 2022
7investing Lead Advisor Maxx Chatsko's top stock to buy in January 2022 is developing a novel technology platform that's well-positioned to address some of the biggest challenges facing gene therapy...
By Maxx Chatsko
Article
Dicerna Pharmaceuticals Deep Dive: October 2021
Dec 28, 2021
For the first time ever, we are releasing an active recommendation to the general public as three-time recommendation Dicerna Pharmaceuticals was acquired by Novo Nordisk in a $3.3 billion deal.
By Maxx Chatsko
Premium Advisor Update
Can Better Antibodies Disrupt Cell Therapy?
Dec 20, 2021
By Maxx Chatsko
Podcast
Investing in Emerging Markets with Perth Tolle
Dec 16, 2021
7investing Lead Advisors Matt Cochrane and Maxx Chatsko chat with Perth Tolle about investing in emerging markets as a global citizen who respects economic and personal freedoms.
Financial Services
Video
Maxx’s Top Stock for December 2021
Dec 1, 2021
7investing Lead Advisor Maxx Chatsko's top stock to buy in December 2021 has just de-risked the entire therapeutic modality of gene therapy -- and Wall Street is entirely misunderstanding the...
By Maxx Chatsko
Article
Think Long Term, but Focus on Your Five-Meter Targets
Nov 21, 2021
Take care of business before getting too carried. Invest in companies that do the same.
By Maxx Chatsko
Video
Maxx’s Top Stock for November 2021
Nov 1, 2021
7investing Lead Advisor Maxx Chatsko's top stock to buy in November 2021 is at the very beginning of an inflection point in its growth trajectory.
By Maxx Chatsko
Article
Navigating Inflation and Interest Rates with Your Hard-Earned Money
Oct 22, 2021
Even long-term investors should acknowledge the role that Fed policy is playing in stock valuations.
By Maxx Chatsko
Podcast
Blue-Sky Thinking in Synthetic Biology
Oct 19, 2021
What will it take for synthetic biology to live up to its promise? 7investing Lead Advisor Maxx Chatsko talks with visionary scientist Andrew Hessel about pushing the envelope of living technologies ...
By Maxx Chatsko
Premium Advisor Update
Drug Development is Risky. Let’s Count the Ways.
Oct 14, 2021
By Maxx Chatsko
Podcast
7investing Explains: How are Medical Devices and Genetic Tests Regulated?
Oct 14, 2021
Health care investors often focus on drug products, but medical devices present unique investing opportunities, too. 7investing Lead Advisors Simon Erickson, Dana Abramovitz, and Maxx Chatsko provide...
Health Care Technology
Article
Can Your Gene Editing Stocks Survive the End of Momentum?
Oct 8, 2021
There are both opportunities and challenges to modifying DNA for therapeutic applications, but objective information is scarce.
By Maxx Chatsko
